Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial - Barco, Stefano; Voci, Davide; Held, Ulrike; Sebastian, Tim; Bingisser, Roland; Colucci, Giuseppe; Dürschmied, Daniel; Frenk, André; Gerber, Bernhard; Götschi, Andrea; Konstantinides, Stavros V; Mach, François; et al. (The lancet. Haematology, 2022)
Published online June 29, 2022